Current Fornas 2025 supports simvastatin and atorvastatin at FKTP. Rosuvastatin 10 mg is marked for PRB with a maximum of 60 tablets/month, so the policy question is expansion or step-up positioning rather than treating all three rungs as having identical access.
Current INAPROC extracts show a modest acquisition-price gap across the rungs, although rosuvastatin 20 mg requires two 10 mg tablets under the listed strength.
PERKI Panduan Tatalaksana Dislipidemia 2022 and international guidance (ESC/EAS 2019; ACC/AHA; NICE NG238) favour moderate-to-high-intensity statin therapy for established ASCVD, so the policy question is whether the incremental event reduction of higher-intensity rungs justifies the modest incremental drug cost and intensity-related harms.
Stroke (19.4%) and ischaemic heart disease (14.4%) are Indonesia's two leading causes of death (Kemenkes 2024), so even small per-patient absolute recurrent-event reductions scale to large averted events at the population level.
Reviewers should test the incremental-LDL and drug-price scenarios before interpreting the base-case sequential ICERs and the efficiency frontier.